The medicine may be “transformational,” but doctors won’t write the script if payers don’t reimburse.
And there’s a veritable alphabet soup of players – everything from KAMs to NAMs, MSLs to MSOLs, PBMs to IDNs, and more – involved in negotiating the path to reimbursement and, ultimately, access for innovative therapies when they hit the market.
Jon Haas, Senior Director, Market Access at Syneos Health, discusses the complex process, how companies can best position their product for access and what really matters to payers in the long run.
For more on value and access in biopharma, check out:
How Competition Affects Market Access for Rare Disease Therapeutics, Part 1
How Competition Affects Market Access for Rare Disease Therapeutics, Part 2
Future-Forward Planning: What Drug and Device Manufacturers Need to Know About Preventive Drug Lists
2021 Update: Non-Personal Promotion: What Do Payers Want?
The Other Path to Access: Strategies for Direct Employer Engagement
サイネオス・ヘルスのポッドキャスト：Trade and Distribution in Pharma: It's Complicated
